Tweet
<img alt="" height="1" width="1" />
AbbVie's hepatitis C treatment helps 96 percent of patients in trial
Reuters
(Reuters) - AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. The trial is being watched closely because of the potential of the treatment, 3D ...
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising resultsFierceBiotech
Enanta Pharmaceuticals Announces 96 Percent SVR12 in SAPPHIRE-I StudyMarketWatch
AbbVie (ABBV) Issues Encouraging SAPPHIRE-I UpdateStreetInsider.com (subscription)
4-traders (press release)
all 6 news articles »
More...